动态[18F]FDG PET/CT提高可切除非小细胞肺癌淋巴结对新辅助化免疫治疗反应的预测
研究纳入86例IIB-IIIB期非小细胞肺癌患者,于基线及新辅助化免疫治疗后术前行[18F]FDG PET/CT,分析原发肿瘤及淋巴结SUVmax和大小的动态变化与淋巴结病理反应的相关性。代谢复合指数(结合原发肿瘤SUVmax变化与治疗后淋巴结SUVmax)预测淋巴结反应的AUC为0.852(95%CI:0.772,0.932),敏感度0.783,特异度0.811。非pCR患者中,PET阳性(N+)组中位无事件生存期17个月,短于PET阴性(N-)组的42个月(p<0.001)。
要点
- 代谢复合指数预测淋巴结反应AUC 0.852(95%CI:0.772,0.932),敏感度0.783,特异度0.811。
- 非pCR患者中,PET阳性(N+)组中位EFS 17个月,短于PET阴性(N-)组42个月(p<0.001)。
- 结合原发肿瘤SUVmax变化与治疗后淋巴结SUVmax,可改善淋巴结反应预测并识别非pCR组预后较差者。
核心结论
- 整合原发肿瘤动态代谢变化与治疗后淋巴结代谢状态,可高效预测可切除非小细胞肺癌淋巴结对新辅助化免疫治疗的反应,并有助于识别非pCR组中预后较差的患者。
研究设计与样本
- 共纳入86例IIB-IIIB期非小细胞肺癌患者,于基线及新辅助化免疫治疗后、手术前行[18F]FDG PET/CT,测量原发肿瘤及淋巴结的SUVmax和大小,分析其动态变化与淋巴结反应的相关性,采用ROC曲线下面积评估预测准确性,Kaplan-Meier分析评估无事件生存期。
诊断标准与关键数值
- 代谢复合指数(结合原发肿瘤SUVmax变化与治疗后淋巴结SUVmax)预测淋巴结反应:AUC 0.852(95%CI:0.772,0.932),敏感度0.783,特异度0.811。
- 非pCR患者中,非pCR/PET(N+)组中位EFS 17个月 vs 非pCR/PET(N-)组42个月,p<0.001。
临床应用与阅片要点
- 阅片时可结合原发肿瘤SUVmax的动态变化与治疗后淋巴结SUVmax,综合评估淋巴结对新辅助化免疫治疗的反应。
- 对非pCR患者,治疗后淋巴结PET阳性(N+)提示预后较差,中位EFS 17个月 vs PET阴性(N-)42个月(p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Accurately predicting the pathological response of lymph nodes to neoadjuvant chemoimmunotherapy in non-small cell lung cancer (NSCLC) remains a challenge. This study aimed to evaluate the effectiveness of [18F]FDG PET/CT imaging in predicting lymph node response to neoadjuvant chemoimmunotherapy in resectable NSCLC. We investigated the predictive value of dynamic changes in imaging features of both primary tumors and lymph nodes.
MATERIALS AND METHODS: A total of 86 patients with stage IIB-IIIB NSCLC were enrolled. [18F]FDG PET/CT scans were conducted at baseline and after neoadjuvant chemoimmunotherapy, but before surgery. SUVmax and size of primary tumors and lymph nodes were measured, and their dynamic changes were analyzed to correlate with nodal response. The predictive accuracy was assessed using the area under the receiver operating characteristic curve. Event-free survival (EFS) was evaluated using Kaplan-Meier analysis.
RESULTS: The metabolism composite index, which combines changes in SUVmax of the primary tumor and post-treatment SUVmax of lymph nodes, significantly improved lymph node response prediction, with an AUC of 0.852 (95% CI: 0.772, 0.932), sensitivity of 0.783, and specificity of 0.811. Patients without a pathological complete response (pCR) had shorter median EFS in the non-pCR/PET (N+) group compared to the non-pCR/PET (N-) group (17 months vs 42 months, p < 0.001).
CONCLUSION: Integrating dynamic metabolic changes in the primary tumor with post-treatment lymph node metabolic status is highly effective in predicting lymph node response to neoadjuvant chemoimmunotherapy. This method also helps identify patients with less favorable prognoses within the non-pCR group.
KEY POINTS: Question How effective is [18F]FDG PET/CT in predicting lymph node response to neoadjuvant chemoimmunotherapy in resectable NSCLC through dynamic changes in metabolic features? Findings The integration of SUVmax changes in the primary tumor with post-treatment SUVmax of lymph nodes achieved a predictive accuracy characterized by an AUC of 0.852. Clinical relevance The use of dynamic metabolic changes from [18F]FDG PET/CT enhances the prediction of lymph node response and helps identify NSCLC patients with poor prognosis, allowing for improved risk stratification and targeted postoperative interventions.
引用
- Li S, Wu J, Li Z, et al. Improving prediction of lymph node response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer via dynamic [18F]FDG PET/CT. Eur Radiol. 2025. PMID: 40483295. doi:10.1007/s00330-025-11729-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。